PT - JOURNAL ARTICLE AU - Seth Toback AU - Anthony M. Marchese AU - Brandy Warren AU - Sondos Ayman AU - Senka Zarkovic AU - Islam ElTantawy AU - Raburn M. Mallory AU - Matthew Rousculp AU - Fahed Almarzooqi AU - Bartlomiej Piechowski-Jozwiak AU - Maria-Fernanda Bonilla AU - Agyad Ebrahim Bakkour AU - Salah Eldin Hussein AU - Nawal Al Kaabi TI - Safety and Immunogenicity of the NVX-CoV2373 Vaccine as a Booster in Adults Previously Vaccinated with the BBIBP-CorV Vaccine: An Interim Analysis AID - 10.1101/2023.03.24.23287658 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.24.23287658 4099 - http://medrxiv.org/content/early/2023/03/29/2023.03.24.23287658.short 4100 - http://medrxiv.org/content/early/2023/03/29/2023.03.24.23287658.full AB - This phase 3 observer-blind, randomized, controlled study was conducted in adults ≥18 years of age to assess the safety and immunogenicity of NVX-CoV2373 as a heterologous booster compared to BBIBP-CorV when utilized as a homologous booster. Approximately 1,000 participants were randomly assigned in a 1:1 ratio to receive a single dose of NVX-CoV2373 or BBIBP-CorV after prior vaccination with 2 or 3 doses of BBIBP-CorV. Solicited adverse events (AEs) were collected for 7 days after vaccination. Unsolicited AEs were collected for 28 days following the booster dose and serious adverse and adverse events of special interest (AESI) were collected throughout the study. For this interim analysis, anti-spike IgG and neutralizing antibodies against SARS-CoV-2 were measured at baseline, day 14, and day 28. The study achieved its primary non-inferiority endpoint and also demonstrated statistically higher neutralization responses of approximately 6-fold when NVX-CoV2373 was utilized as a heterologous booster compared with BBIBP-CorV as a homologous booster. Both vaccines had an acceptably low reactogenicity profile and no new safety concerns were found. Heterologous boosting with NVX-CoV2373 was a highly immunogenic and safe vaccine regimen in those previously vaccinated with BBIBP-CorV.Competing Interest StatementST, AMM, BW, RM, and MR are employees and stockholders of Novavax, Inc. SA, SZ, IET, AEB, SEH, NAK, FA, BP-J, and M-FB have no disclosures to report.Clinical TrialNCT05249816Funding StatementThis work was supported by Cogna Technology Solutions LLC, Abu Dhabi, UAE; and Novavax, Inc., Gaithersburg, MD, USAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Abu Dhabi Health Research and Technology Committee (ADHRTC) ethics committee and the Drugs Department at Ministry of Abu Dhabi Health and Prevention, Dubai, UAE (MOHAP) Regulatory Authority gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesStudy information is available at https://clinicaltrials.gov/ct2/show/NCT05249816, and requests will be considered.